Aldeyra Therapeu (ALDX)

$4.13 -0.55 (-11.67%)
Market Cap 248.26M
Revenue (ttm) 0.00
Net Income (ttm) -33.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 4.02
Profit Margin 0.00%
Debt to Equity Ratio 0.34
Volume 3,399,600
Avg Vol 977,128
Day's Range N/A - N/A
Shares Out 60.18M
Stochastic %K 7%
Beta 0.97
Analysts Strong Sell
Price Target $9.00

Company Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally admini...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 761 4904
Fax: 339 674 6495
Address:
131 Hartwell Avenue, Suite 320, Lexington, United States
DeadInvestor
DeadInvestor Mar. 16 at 2:28 AM
$ALDX Can anyone see volume Pre market Sunday night?
1 · Reply
Smellmahass
Smellmahass Mar. 16 at 2:01 AM
$ALDX Someone knows something.
0 · Reply
whatabigcockyouhave
whatabigcockyouhave Mar. 16 at 2:00 AM
$ALDX there it is, the final bull trap, i expected it friday.
0 · Reply
DanishVikings
DanishVikings Mar. 16 at 1:00 AM
$ALDX $SLS both of my gems are up AH - i love it
1 · Reply
hoodrichh
hoodrichh Mar. 16 at 1:00 AM
$ALDX 😂😂😂
0 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers Mar. 16 at 12:32 AM
$ALDX Let the someone knows something comments commence On 8000 shares overnight 😂😂 Hope they pump it tomorrow into the decision
1 · Reply
ook__
ook__ Mar. 16 at 12:29 AM
$ALDX @TrialWatchdog lol I hope you lose everything
1 · Reply
TrialWatchdog
TrialWatchdog Mar. 16 at 12:26 AM
$ALDX breaking news 🚨retail buyer with $2500 moves stock 20% 8pm Sunday night before PDUFA.
2 · Reply
UpAndDownUpAndDown
UpAndDownUpAndDown Mar. 16 at 12:16 AM
$ALDX something brewing. Looking good. She’s going to fly tomorrow.
0 · Reply
TrialWatchdog
TrialWatchdog Mar. 16 at 12:10 AM
$ALDX perfect time for longs to get out alive!
0 · Reply
Latest News on ALDX
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 7:01 AM EST - 25 days ago

Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst

Dec 30, 2025, 6:26 PM EST - 2 months ago

Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst

Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript

Dec 16, 2025, 10:09 AM EST - 3 months ago

Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Dec 15, 2025, 7:30 PM EST - 3 months ago

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript

Nov 13, 2025, 3:11 PM EST - 4 months ago

Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Nov 13, 2025, 7:00 AM EST - 4 months ago

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 11, 2025, 7:01 AM EST - 4 months ago

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

Nov 6, 2025, 7:00 AM EST - 4 months ago

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Oct 28, 2025, 7:01 AM EDT - 4 months ago

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

Oct 10, 2025, 4:32 AM EDT - 5 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALEC BDTX CHRS

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:01 AM EDT - 6 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aug 28, 2025, 7:01 AM EDT - 7 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aug 19, 2025, 7:01 AM EDT - 7 months ago

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 7:01 AM EDT - 7 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Jul 24, 2025, 7:00 AM EDT - 8 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jul 17, 2025, 7:00 AM EDT - 8 months ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

Jul 2, 2025, 9:23 PM EDT - 9 months ago

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Jun 26, 2025, 7:00 AM EDT - 9 months ago

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jun 17, 2025, 7:00 AM EDT - 9 months ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 29, 2025, 7:01 AM EDT - 10 months ago

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law

May 7, 2025, 4:07 PM EDT - 11 months ago

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

May 7, 2025, 8:46 AM EDT - 11 months ago

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman

May 6, 2025, 4:42 PM EDT - 11 months ago

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss

May 6, 2025, 3:48 PM EDT - 11 months ago

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 5, 2025, 6:34 PM EDT - 11 months ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 5, 2025, 4:00 PM EDT - 11 months ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation

May 5, 2025, 3:38 PM EDT - 11 months ago

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

May 3, 2025, 7:18 AM EDT - 11 months ago

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company

May 1, 2025, 8:08 AM EDT - 11 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law

Apr 30, 2025, 3:38 PM EDT - 11 months ago

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law

Apr 29, 2025, 4:07 PM EDT - 11 months ago

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Apr 29, 2025, 9:49 AM EDT - 11 months ago

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

Apr 28, 2025, 9:00 PM EDT - 11 months ago

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

TTGT

ALDX NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of Pending Securities Investigation - Contact BFA Law if You Lost Money

Apr 28, 2025, 3:46 PM EDT - 11 months ago

ALDX NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of Pending Securities Investigation - Contact BFA Law if You Lost Money

ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law

Apr 27, 2025, 8:20 AM EDT - 11 months ago

ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law

ALDX SHAREHOLDER NEWS: Aldeyra Therapeutics, Inc. 75% Stock Plummet Leads to Securities Investigation - Investors are Urged to Contact BFA Law

Apr 25, 2025, 3:22 PM EDT - 11 months ago

ALDX SHAREHOLDER NEWS: Aldeyra Therapeutics, Inc. 75% Stock Plummet Leads to Securities Investigation - Investors are Urged to Contact BFA Law

ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation – Contact BFA Law if You Lost Money

Apr 25, 2025, 7:36 AM EDT - 11 months ago

ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation – Contact BFA Law if You Lost Money

ALDX NOTICE: A Securities Investigation was initiated on behalf of Aldeyra Therapeutics, Inc. Investors - Contact BFA Law

Apr 24, 2025, 3:18 PM EDT - 11 months ago

ALDX NOTICE: A Securities Investigation was initiated on behalf of Aldeyra Therapeutics, Inc. Investors - Contact BFA Law

ALDX INVESTIGATION: Aldeyra Therapeutics, Inc. is being Investigated for Securities Violations - Investors are Notified to Contact BFA Law

Apr 23, 2025, 3:36 PM EDT - 11 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics, Inc. is being Investigated for Securities Violations - Investors are Notified to Contact BFA Law

LEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Investors are Notified of the Pending Securities Investigation - Contact BFA Law

Apr 23, 2025, 8:18 AM EDT - 11 months ago

LEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Investors are Notified of the Pending Securities Investigation - Contact BFA Law

ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being Investigated - Contact the Firm if You Lost Money

Apr 22, 2025, 3:23 PM EDT - 11 months ago

ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being Investigated - Contact the Firm if You Lost Money

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity

Apr 21, 2025, 10:52 AM EDT - 11 months ago

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity

DeadInvestor
DeadInvestor Mar. 16 at 2:28 AM
$ALDX Can anyone see volume Pre market Sunday night?
1 · Reply
Smellmahass
Smellmahass Mar. 16 at 2:01 AM
$ALDX Someone knows something.
0 · Reply
whatabigcockyouhave
whatabigcockyouhave Mar. 16 at 2:00 AM
$ALDX there it is, the final bull trap, i expected it friday.
0 · Reply
DanishVikings
DanishVikings Mar. 16 at 1:00 AM
$ALDX $SLS both of my gems are up AH - i love it
1 · Reply
hoodrichh
hoodrichh Mar. 16 at 1:00 AM
$ALDX 😂😂😂
0 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers Mar. 16 at 12:32 AM
$ALDX Let the someone knows something comments commence On 8000 shares overnight 😂😂 Hope they pump it tomorrow into the decision
1 · Reply
ook__
ook__ Mar. 16 at 12:29 AM
$ALDX @TrialWatchdog lol I hope you lose everything
1 · Reply
TrialWatchdog
TrialWatchdog Mar. 16 at 12:26 AM
$ALDX breaking news 🚨retail buyer with $2500 moves stock 20% 8pm Sunday night before PDUFA.
2 · Reply
UpAndDownUpAndDown
UpAndDownUpAndDown Mar. 16 at 12:16 AM
$ALDX something brewing. Looking good. She’s going to fly tomorrow.
0 · Reply
TrialWatchdog
TrialWatchdog Mar. 16 at 12:10 AM
$ALDX perfect time for longs to get out alive!
0 · Reply
BlakeCanyon50
BlakeCanyon50 Mar. 16 at 12:10 AM
$ALDX
0 · Reply
BlakeCanyon50
BlakeCanyon50 Mar. 16 at 12:08 AM
$ALDX 🤔
0 · Reply
idk88
idk88 Mar. 16 at 12:06 AM
$ALDX
0 · Reply
Istvan36_
Istvan36_ Mar. 15 at 11:31 PM
$ALDX when the market is open please ?
0 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers Mar. 15 at 11:22 PM
$MU $LUNR $LULU $META VIP Subs Your weekly newsletter is live now and in your inboxes. Enjoy. Some really good big name set ups this week. 7 earnings plays Lots of day trade ideas. SPY/SPX set ups And its D-DAY for $ALDX
2 · Reply
Noahman
Noahman Mar. 15 at 10:44 PM
$ALDX rolling the dice here in vegas this afternoon. Here's for a winning # tomorrow. Cheers 🍻
0 · Reply
ook__
ook__ Mar. 15 at 10:09 PM
$ALDX why do believe this?
1 · Reply
DanishVikings
DanishVikings Mar. 15 at 9:57 PM
$ALDX "AbbVie's commitment: The fact that a giant like AbbVie has put a big bag of money into a licensing deal after putting the latest data in serves as a form of "validation" of the application. They rarely make these kinds of deals if they see a high risk of another rejection."
1 · Reply
Aksunbay
Aksunbay Mar. 15 at 9:38 PM
$ALDX
0 · Reply
TrialWatchdog
TrialWatchdog Mar. 15 at 9:22 PM
$ALDX inb4 “FDA is corrupt”, “This isn’t their only trial”, “averaging down at 80 cents here”
0 · Reply
DanishVikings
DanishVikings Mar. 15 at 9:07 PM
$ALDX shorters are betting on 35% chance of denial tomorrow.. xD
2 · Reply
DanishVikings
DanishVikings Mar. 15 at 9:02 PM
$ALDX cant wait to hear all the babies (shorters) cry tomorrow when this blast through the roof and travels north of $10 to never look back!
1 · Reply